



ASX ANNOUNCEMENT

29 April 2021

Recall of product

29 April 2021 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has received notice from one of its customers that the customer has commenced a class III recall in respect of 250 units of 50ml medicinal cannabis oil products recently released to the Australian market. A class III recall is not a safety-related recall and is undertaken where a deficient product is not likely to cause adverse health consequences.

Cann understands that 11 units have been supplied to patients and the balance of the units are being retained by the customer's distributor.

The products were manufactured and released by a third party GMP licensed manufacturer, engaged by Cann, using ingredients which included a starting material supplied by another third party. The recall follows the identification of particulate matter in a subsequent batch of the product by Cann's manufacturer, who then notified Cann of the issue.

In line with the Therapeutic Goods Administration's (**TGA**) processes, the sponsor of the product in Australia (the customer's distributor) is liaising with the TGA to coordinate the recall. Cann is working with its customer, manufacturer and supplier to identify the cause of the issues in relation to these products.

Authorised for release by the Chairman of the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@cann grouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.cann grouplimited.com | www.satipharm.com